• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Exp Nephrol . Factors associated with SARS-CoV-2 antibody titers and prognosis of breakthrough infection in hemodialysis patients

tetano

Editor, Senior Moderator
Clin Exp Nephrol


. 2022 Feb 8.
doi: 10.1007/s10157-022-02188-y. Online ahead of print.
Factors associated with SARS-CoV-2 antibody titers and prognosis of breakthrough infection in hemodialysis patients


Masataro Toda[SUP] 1 [/SUP], Ayumi Yoshifuji[SUP] 2 [/SUP], Kan Kikuchi[SUP] 3 [/SUP], Motoaki Komatsu[SUP] 1 [/SUP], Kentaro Fujii[SUP] 1 [/SUP], Ai Kato[SUP] 1 [/SUP], Takahide Kikuchi[SUP] 4 [/SUP], Atsushi Nakazawa[SUP] 5 [/SUP], Munekazu Ryuzaki[SUP] 1 [/SUP]



Affiliations

Abstract

Background: The mortality rate of Coronavirus disease 2019 (COVID-19) is extremely high in hemodialysis patients (HDP). These patients also develop lower antibody titers after vaccination. Therefore, factors associated with antibody titers and vaccine efficacy in HDP with breakthrough infection need to be investigated.
Methods: We measured anti-S1 antibody titers in HDP (n = 104) and controls (n = 35), evaluating the influence of background on HDP by multivariable regression analysis. We classified 26 HDP patients admitted with COVID-19 into the unvaccinated (n = 15) and breakthrough infection group (n = 11), performing between-group comparisons of laboratory findings and prognosis. Vaccinated COVID-19 patients were classified into HDP and non-HDP controls, and compared the relationship between antibody titer and severity, and the prognosis of breakthrough infection.
Results: The antibody titer was significantly lower in the HDP group than in the control group. Among HDP, age and smoking history were significantly independent factors associated with antibody titer. The breakthrough infection group had significantly better laboratory findings (KL-6 and LDH), severity, and hospitalization period than the unvaccinated group even if antibody titers were lower than the known threshold for neutralization (p < 0.05). There was no significant difference in prognosis between the HDP and non-HDP with breakthrough infection. Severity of COVID-19 tended to be higher with lower antibody titer in non-HDP, but not in HDP.
Conclusion: Vaccines improved the severity of COVID-19 and hospitalization period of breakthrough infection in HDP, although HDP, especially in elderly smokers had lower antibody titers than control. There was no significant association between antibody titer and severity in HDP.

Keywords: Antibody titer; Breakthrough infection; COVID-19; Hemodialysis; Vaccine.
 
Back
Top Bottom